PeptideEmergingFat Loss
Eloralintide
Amylin receptor agonist (investigational, long-acting)
Also known as LY3841136
Typical dose
1–9 mg
once weekly · SubQ
What is Eloralintide?
An investigational long-acting, selective AMYLIN receptor agonist (Eli Lilly, LY3841136) for weight management — once-weekly SubQ injection. Same amylin class as cagrilintide, engineered for weekly dosing.
How Eloralintide works
Selective amylin (AMY1R/calcitonin-receptor) agonist — suppresses appetite, slows gastric emptying, promotes satiety via the amylin pathway (distinct from GLP-1). Fatty-acid-acylated for weekly depot dosing; no oral form.
Benefits & uses
- Weight loss (up to ~20% at 48 wks, 9 mg dose)
- Appetite/satiety via amylin (complements GLP-1)
- Once-weekly
- Dose-dependent, generally well tolerated
Common uses: Fat loss / obesity (amylin-pathway).
Fat Loss
Eloralintide dosage
- Typical dose
- Once-weekly SubQ; Phase 2 tested 1, 3, 6, 9 mg + escalation arms (3→9, 6→9 mg for GI tolerability)
Eloralintide side effects
- Nausea (~33% at 9 mg)
- Fatigue (~43% at 9 mg)
- Vomiting
- GI effects worst on initiation
Warnings & monitoring
- Investigational — no approved dosing; titrate for GI tolerability
- Not for pregnancy
- SubQ, once-weekly
Preparation & storage
- Reconstitution
- Reconstitute with BAC water per product labelling; dose by volume.
Commonly stacked with
Track Eloralintide in Protokol.
Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.
